Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer
暂无分享,去创建一个
S. Baxi | A. Ho | D. Pfister | H. Schöder | R. Ghossein | R. Tuttle | E. Sherman | C. Sima | L. Dunn | S. Haque
[1] M. Brose,et al. Targeting Vascular Endothelial Growth Factor Receptor in Thyroid Cancer: The Intracellular and Extracellular Implications , 2010, Clinical Cancer Research.
[2] R. Tuttle,et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. , 2001, Surgery.
[3] M. Santoro,et al. BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.
[4] Seungwon Kim,et al. Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer , 2006, Clinical Cancer Research.
[5] A. J. Garrett,et al. CANCER XENOGRAFTS IN NUDE MICE , 1976, The Lancet.
[6] J. Llovet,et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.
[7] Jiachao Liang,et al. Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Viglietto,et al. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene , 1999, Oncogene.
[9] Sung-Bae Kim,et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.
[10] Mithat Gonen,et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.
[11] B. Goh,et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. , 2010, The Lancet. Oncology.
[12] Mahitosh Mandal,et al. Concurrent Cetuximab and Bevacizumab Therapy in a Murine Orthotopic Model of Anaplastic Thyroid Carcinoma , 2007, The Laryngoscope.
[13] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[14] L. Bastholt,et al. Motesanib diphosphate in progressive differentiated thyroid cancer. , 2008, The New England journal of medicine.
[15] M. Saji,et al. Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. , 2003, Annals of clinical and laboratory science.
[16] R. Paschke,et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.
[17] L. Bresler*,et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. , 1999, The Journal of endocrinology.
[18] Thomas Krause,et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. , 2012, The Lancet. Oncology.
[19] M. Saji,et al. Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. , 2002, Thyroid : official journal of the American Thyroid Association.
[20] I. Rossi,et al. Response of Anaplastic Thyroid Tumors to VEGF-Trap, an Anti-Angiogenic Agent , 2009 .
[21] L. Bresler*,et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[22] C. Andresen,et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment , 2015, Cancer.
[23] G. Yancopoulos,et al. VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] Andrea B Troxel,et al. Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] E. Vokes,et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Fumoleau,et al. Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors , 2012, Clinical Cancer Research.
[27] G. Yancopoulos,et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.